Searched for
STELARA
JNJ stock price today: Why Johnson & Johnson shares dropped despite strong 2026 forecast? Here's what investors are watchingJNJ stock price today: Johnson & Johnson stock saw a dip even as the company projected robust 2026 sales and profit figures. Legal issues, ...- Biocon gets Health Canada nod for biosimilars Yesintek, Yesintek IVBiocon Biologics has made strides in the healthcare sector by obtaining Health Canada’s approval for Yesintek and Yesintek IV, its latest a...
- Johnson & Johnson earnings beat estimates on strong cancer drug salesJohnson & Johnson's first-quarter revenue and profit exceeded Wall Street expectations, driven by strong cancer drug sales. The company rai...
- Biocon shares in focus after successful results of Yesintek in Phase 3Biocon's shares have risen by 18.31% over the past year. However, year-to-date (YTD), the stock has dropped by 9.59%. In the last six month...
- Biocon shares in focus after subsidiary launches biosimilar alternative to Stelara in the USBiocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune conditions, offering ...
- Biocon shares zoom 4% as Jefferies upgrades to "hold" amid positive news inflow, sets Rs 400 targetBiocon share price: This upgrade reflects a more positive outlook on the company following recent favorable news flow, particularly concern...
- Biocon Biologics gets US nod to launch Stelara biosimilarBiocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions...
- Biocon shares fall 6% after Q2 net profit dives 84%. What should investors do?Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...
- Biocon settles with Janssen to commercialise biosimilar products in Europe, Canada, JapanBiocon Biologics has entered into a settlement and licence agreement with Janssen Biotech Inc, Janssen Sciences Ireland, and Johnson & John...
- J&J Q2 Results: Pharma major beats Wall Street estimates on strong drug salesJohnson & Johnson beat estimates for second-quarter profit and revenue on Wednesday, driven by strong sales of its drugs, including cancer ...
- J&J acquires experimental skin disorder drug for $1.25 billionNUMAB THERAPEUTICS-JOHNSON&JOHNSON/M&A (UPDATE 2, PIX)UPDATE 2-J&J acquires experimental skin disorder drug for $1.25 billion
- Stocks in news: Suven Pharma, MOIL, Adani stocks, ICICI Lombard, VedantaSuven Pharmaceuticals and Cohance Lifesciences signed a definitive agreement to merge their businesses, which will further strengthen the f...
- Biocon Biologics inks licence pact with Janssen for biosimilar productThe agreement licenses the company to launch in the US in February 2025, once approved by the US Food and Drug Administration(USFDA), Bioco...
- J&J Q4 Results: Profit edges past Street view after deals delay Stelara competitionJohnson & Johnson on Tuesday reported quarterly results just above Wall Street expectations, helped by strong sales of its blockbuster psor...
- Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumabCuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based ...
- J&J issues cautious 2023 forecast, shares fallThe company was "responsibly optimistic" about 2023, Chief Financial Officer Joseph Wolk said on a conference call, pointing to fierce comp...
- J&J expects COVID vaccine sales to jump as much as 46% in 2022Johnson & Johnson said on Tuesday it expects to generate as much as $3.5 billion from the sale of its COVID-19 vaccine this year compared t...
- Johnson & Johnson plans to split into two companiesThe healthcare company will separate its consumer health business into a new publicly traded company and is aiming to complete the planned ...
- Decoding the impact of Ilumya, Sun Pharma's first biologic drug approved by the US FDALast year Sun Pharma signed another deal with South Korea's Samsung Biologics to get the drug manufactured on approval.
- Sun Pharma gets USFDA nod for plaque psoriasis drugThe FDA approval of the drug was supported by data from the pivotal phase-3 resurface clinical development program, it said.
Load More
